ReviewJournal of personalized medicine2015
Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe.
Review in Journal of personalized medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Milestone to Ensure Safety and Efficacy of Companion Diagnostic (CDx) That Support Treatment Decisions in Cancer Patients.Diagnostics (Basel, Switzerland) · 2026Review
- A User-Centered Service Model for Accelerating COVID-19 Diagnostic Innovation: The RADx-rad Dx Core Approach.IEEE open journal of engineering in medicine and biology · 2025Article
- Insights into post-marketing clinical validation of companion diagnostics with reference to the FDA, EMA, PMDA, and MFDS.Molecular therapy. Methods & clinical development · 2024Review
- Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse.Heredity · 2022Article
- Toward Precision Medicine in ADHD.Frontiers in behavioral neuroscience · 2022Review
- Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?The EPMA journal · 2017Review
- Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine.The EPMA journal · 2015Review
- Big Data: transforming drug development and health policy decision making.Health services & outcomes research methodologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.